跳至主要内容
临床试验/CTRI/2023/07/055462
CTRI/2023/07/055462招募中不适用

An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients

Pfizer Ltd4 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2023年7月31日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Pfizer Ltd
入组人数
3,000
试验地点
4
主要终点
to evaluate the epidemiological burden of mild, moderate and severe AD,vitiligo,and AA across enrolled dermatology centers

研究概览

简要总结

The objective of this registry is to evaluate the epidemiological burden of mild, moderate and severe AD, vitiligo, and AA across enrolled dermatology centers.

Elucidate the current diagnostic criteria and grading modalities for AD, vitiligo, and AA in India.

There is no study-related intervention.

研究设计

研究类型
Observational

入排标准

年龄范围
2.00 Year(s) 至 64.00 Year(s)(—)
性别
All

入选标准

  • Be aged between 2 and 64 years old.
  • Clinical diagnosis of Vitiligo, AA or AD.
  • Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

排除标准

  • Patients meeting any of the following criteria will not be included in the study:
  • Not willing to provide written informed consent.
  • Not willing for a follow-up visit.

结局指标

主要结局

to evaluate the epidemiological burden of mild, moderate and severe AD,vitiligo,and AA across enrolled dermatology centers

时间窗: followup visits take place at intervals at the investigators discretion.

次要结局

  • To elucidate the current diagnostic criteria and grading modalities for AD,vitiligo,and AA in India.(followup visits take place at intervals at the investigators discretion.)

研究者

发起方
Pfizer Ltd
申办方类型
Pharmaceutical industry-Global

研究点 (4)

Loading locations...

相似试验